Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Resmetirom (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions
- 16 Apr 2013 Results discussed in a First Times Disclosures session at National Meeting of the American Chemical Society.
- 29 Nov 2012 Status changed from recruiting to completed.
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.